A Phase 1, Randomized, Blinded, Placebo-Controlled, Single-Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BIIB076 in Healthy Volunteers and Subjects With Alzheimer's Disease
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
At a glance
- Drugs BIIB 076 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Sponsors Biogen
- 09 Jan 2019 Planned End Date changed from 1 Aug 2019 to 2 Jul 2019.
- 09 Jan 2019 Planned primary completion date changed from 20 Jun 2019 to 2 Jul 2019.
- 10 Aug 2018 Status changed from active, no longer recruiting to recruiting.